Asthma Innovation Research
Charity registration number: 1168495
Asthma Innovation Research
Annual Report
and Financial Statements
for the Year Ended 1 January 2024
1
Asthma Innovation Research
(Registration number 1168495)
Contents
| Page | |
|---|---|
| Reference and Administrative Details | 3 |
| Trustees’ Report | 4 |
| Statement of Trustees’ Responsibilities | 7 |
| Statement of Financial Activities | 8 |
| Balance Sheet | 10 |
| Notes to the Financial Statements | 11 to 16 |
2
Asthma Innovation Research
(Registration number 1168495)
Reference and Administrative Details
| Charity name Charity Registration Number Companies House registration Legal structure Trustees Principal address Website and Email Bankers Custodian trustees holding assets |
The legal name is “Asthma Innovation Research” 1168495 Registered with Charity Commission in England & Wales CE007169 Charitable Incorporated Organisation “CIO” Registered with Companies House in England & Wales Governing document is the Trust Deed establishing the charity. The trustees are all individuals. Dr Jonny Coppel Dr Rahul Chodhari (Chairman) Dr Azmain Chowdhury Dr Dominic Fenn Dr Lucy Azimzadeh Dr Jessica Kearney Dr Tom Wright Apartment 55 Warwick Building 366 Queenstown Road London SW11 8NJ www.asthmainnovationresearch.co.uk asthmainnovationresearch@gmail.com Metro Bank plc Southampton Row, London, WC1B 5HA There are no assets held by any custodian trustee or nominee on behalf of the charity |
|---|---|
3
Asthma Innovation Research
(Registration number 1168495)
Trustees’ Report
The trustees present the annual report together with the financial statements of the charity for the year ended 1 January 2024.
Objects and activities of the charity
The purposes of the charity are set out in its governing document.
The charity’s governing document is a constitution that was drawn up and was approved by the Charity Commission upon registering on 28 July 2016 and then again after being updated on 27[th] July 2023.
The object of AIR is to relieve sickness and promote good health, predominantly in the paediatric population, by reducing mortality and morbidity caused by a range of modifiable health conditions including asthma, in particular but not exclusively by:
-
(1) training medical students to educate school children, parents and other members of the community about these conditions and increase their knowledge of emergency protocols;
-
(2) promoting the discussion, the consideration of, and research into these modifiable health conditions;
-
(3) publishing results of research and discussion on matters of modifiable health conditions;
-
(4) hosting educational events including, but not limited to, conferences and lectures on topics of importance; and
-
(5) providing opportunities to encourage the exchange of ideas.
The main activities undertaken in relation to those purposes during the year.
The main activities undertaken in relation to these purposes are:
-
(1) Managing the asthma teaching programmes currently set up in University College London medical school, Cardiff University, Imperial College University, King’s College London University and Cambridge University. These projects involve training medical students to go into primary and secondary schools and teach school children about asthma to reduce the stigma around the condition and to improve knowledge of the condition and the emergency protocols.
-
(2) Attempting to set up the teaching programmes in more medical schools.
-
(3) The distribution and advertising of asthma educational booklets that we had previously developed.
4
Asthma Innovation Research
(Registration number 1168495)
-
(4) Assisting with the development and piloting of Project Health Resilience, an education and youth-setting based health literacy pilot delivered by doctors and public health professionals for young Londoners aged 16 to 19 years.
-
(5) Assisting with the development and piloting of training medical students to assist in delivering a breast cancer awareness presentations in association with Befriend Your Boobs (BYB) presentations.
The main activities undertaken during the year to further the charity's purpose for the public benefit.
The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity.
The charity's main objectives and achievements for the year
In this time period we had the following achievements:
Asthmanauts & Princess Asma:
In 2023, following the success of our campaign in 2022 in Camden and Islington Boroughs we have continued to provide copies of the booklet to health care providers within and beyond this vicinity. We were approached by several individual asthma services to offer support and copies of our booklet including the Children's Atopy clinic at the Royal Free Hospital. The booklet here was very well received and has since attracted further interest in neighbouring Boroughs. As previously we continue to monitor downloads from our website and encourage online use via our website and other AIR projects. We are now hoping to establish a greater user base of the booklet with firm groundings in the Whittington Hospital as well as the Royal Free Hospital trust.
PHR annual update report:
Project Health Resilience (PHR) is an education and youth-setting based health literacy pilot delivered by doctors and public health professionals for young Londoners aged 16 to19 years. The project has been led and developed by Dr Leonora Weil working with Dr Clovis Rau, Dr Carys Lewis, Dr Gabriella Landy, Dr Aidan Cross, Astrid Whight, Chrissie Dillon, Mike Morlock, Ana Zuriaga Alvaro, Jo Inskip, Dalya Marks and Dr Jonny Coppel. PHR continues to expand as a multistakeholder partnership that includes UKHSA London, the NHS Legacy and Health Equity Partnership, Camden Council Public Health Team, London School of Hygiene and Tropical Medicine (LSHTM), the Greater London Authority, Health Education England, NHS trusts and Asthma Innovation Research (AIR).
5
Asthma Innovation Research
(Registration number 1168495)
Following a pre-pilot in 2021 in a school in Camden, funding was secured from the NHS Legacy and Health Equity Partnership for a further one year pilot and evaluation in partnership with LSHTM. Data was collected between March 2023 and October 2023 and is currently being analysed. Up until January 2024, 66 sessions were conducted across 8 boroughs, in 12 settings, with over 1000 student attendances. This includes sessions for SEND settings, care leavers and young people in vulnerable circumstances. The core team includes appointed Clinical Fellows in Emergency Medicine, Primary Care, Public Health and Mental Health. There has also been successful enrolment of ‘Project Health Resilience Ambassadors’ (clinicians in training from the different specialties who are volunteer facilitators) helping expand session capacity and availability. Ambassadors complete training conducted both face to face and online, that has included a panel discussion with youth representatives, cultural competency training, whilst also being an opportunity for statutory mandatory checks alongside the formal session facilitation training.
The PHR team continues to collaborate with Peer Outreach Workers and youth organisations such as NHS Digital Health Ambassadors, Thrive LDN, The Hive and the Partnership for Young London to ensure that the sessions are co-produced with young people. A website with the dual purpose of a booking system and post-course summary platform has been established. Presentations have included showcasing at: the Royal College of General Practitioners One Day Essentials in Adolescent Medicine in September 2023; as a poster at the UKHSA National Conference in November 2023; and a presentation at the NHS Legacy and Health Equity Partnership Community and Health Partnerships Conference in March 2024. The team have also been invited to the London Virtual Festival of Learning for Public Health Professionals to present on Project Health Resilience in the summer of 2024.
Asthma Schools Education Programme:
The schools programme has continued its work training up medical students in Cardiff, Cambridge, UCL, KCL and Imperial medical schools. Additionally training of new medical students began in Oxford university. Over 50 medical students were trained up to teach over 600 school children. There were no incidents during the year and the feedback from students and schools has been very positive.
Befriend Your Boobs:
The BYB/AIR collaboration has began in Ernest with a promising pilot underway involving medical students. As part of the BYB/ AIR collaboration we have trained 8 students in 2023 over two dates. 3 students taught at Immanuelle School on 23/11/23. 6 students taught at Kingsbury School on 27/11/23. The teaching has been very well received by the students, including featuring in one school newsletter. Positive feedback about the medical students includes one trainee saying “the students were a joy today: diligent, kind, competent, willing to learn".
Change in constitution:
Changes to the constitution were made and approved by the members of the charity as well as the charity commission. The main changes related to the objects of the charity as described above. In summary, the changes provides the charity with the remit to work on health educational projects relating to medical conditions other than asthma.
6
Asthma Innovation Research
(Registration number 1168495)
Learn Live:
The charity was approached to collaborate with the NHS campaign ‘Askaboutasthma’. Two of the charity’s members, Patricia Lutalo and Jonny Coppel, gave video recordings as part of an asthma Q and A session which was broadcast to 5399 people live and then subsequently 9331 people have watched it on demand.
The contribution of volunteers during the year.
Volunteers, in terms of the Trustees and others have regularly given their time and resources during this period with no drain on the charity’s funding.
Financial Review
The financial position of the charity at 1 January 2024 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-
| Net income/(expenditure) Unrestricted revenue funds for general purposes of the charity Restricted funds Total Funds |
2023 £ (39) 2,193 - 2,193 |
2022 £ (388) 2,232 - 2,232 |
|---|---|---|
Total income of £13 was generated during the financial year 2023/2024, compared to £nil raised in the previous 2022/23 year.
On 1/1/24, AIR had £2,193, which comprises general funds, and there were no restricted funds. There are no concerns about the charity’s ability to continue. These unrestricted funds of £2,193 should drive the educational projects forward.
Outlook for 2024
Our main areas of activity in 2024 are predicted to be:
-
The Asthma Schools Education Project. We will continue to offer sessions where possible either face to face or virtually. As always, we will continue to try to spread the project to new medical schools. A social media campaign is being planned in order to expand our network of schools that we can present to/at.
-
The further distribution of Asthmanauts will be reviewed.
-
Complete pilots and develop sustainable plans for the future of both Project Health Resilience and BYB.
7
Asthma Innovation Research
(Registration number 1168495)
Statement of Trustees’ Responsibilities
The trustees are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.
The law applicable to charities requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:
-
select suitable accounting policies and then apply them consistently;
-
observe the methods and principles in the Charities SORP;
-
make judgements and estimates that are reasonable and prudent;
-
state whether applicable accounting standards have been followed, subject to any material departures
-
disclosed and explained in the financial statements; and
-
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the
-
charity will continue in business.
•
The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations, and the provisions of the constitution. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Approved by the trustees of the charity on 3[rd] June 2024 and signed on its behalf by:
......................................... ………………………………….. Dr Jonny Coppel Dr Jess Kearney Trustee Trustee
8
Asthma Innovation Research
(Registration number 1168495)
Statement of Financial Activities (including Income & Expenditure Account) for the Year Ended 1 January 2024
| SORP | Current Year | Prior Year | |||
|---|---|---|---|---|---|
| Ref | Unrestricted | Restricted |
Total | Total | |
| Funds | Funds | Funds | Funds | ||
| £ | £ | £ | £ | ||
| Income & Endowments | |||||
| from: | |||||
| Donations & Legacies | A1 | 13 | - |
- | - |
| Charitable activities | A2 | - | - |
- | - |
| Other trading activities | A3 | - | - |
- | - |
| Investments | A4 | - | - | - | - |
| Other | A5 | - | - | - | - |
| Total income | A | 13 | - | - | - |
| Expenditure on: | |||||
| Raising funds | B1 | - | - | - | - |
| Charitable activities | B2 | 51 | - | 51 | 388 |
| Other | B3 | - | - | - | - |
| Total Expenditure | B | 52 | - | 52 | 388 |
| Net income/(expenditure) | A-B | (39) |
- | (39) | (388) |
| for the year | |||||
| Reconciliation of funds:- | E | ||||
| Total funds brought | 2,232 | - | 2,232 | 2,620 | |
| forward | |||||
| Total funds carried | 2,193 | - | 2,193 | 2,232 | |
| forward |
The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.
The statement of financial activities includes all gains and losses in the year. All incoming resources and resources expended derive from continuing activities.
In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity’s activities.
The notes attached on pages 11 to 16 form an integral part of these accounts.
9
Asthma Innovation Research
(Registration number 1168495)
Analysis of prior year total funds, as required by paragraph 4.2 of the SORP
| SORP Ref Income & Endowments from: Donations & legacies A1 Expenditure on: Raising funds B1 Charitable activities B2 Total expenditure B Net income for the year Net movement in funds Reconciliation of funds:- E Total funds brought forward Total funds carried forward |
Prior Year Unrestricted Restricted Total Funds Funds Funds 2023 2023 2023 £ £ £ - - - |
|---|---|
| - - - (388) - (388) |
|
| (388) - (388) |
|
| (388) - (388) |
|
| (388) - (388) |
|
| 2,620 - 2,620 |
|
| 2,232 **2,232 ** |
The statement of financial activities includes all gains and losses in the year. All incoming resources and resources expended derive from continuing activities.
The notes attached on pages 11 to 16 form an integral part of these accounts.
10
Asthma Innovation Research
(Registration number 1168495)
Balance Sheet as at 1 January 2024
| SORP Note Ref Current assets B Debtors 7 B2 Cash at bank and in hand B4 Creditors: Amounts falling due within one year 8 C1 The total net assets of the charity Funds of the charity: Unrestricted funds D3 Restricted funds Total funds 9 |
2024 2023 £ £ - - 2,193 2,232 - - |
|---|---|
| 2,193 2,232 |
|
| 2,193 2,232 - |
|
| 2,193 2,232 |
The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.
Approved by the trustees of the charity on 3[rd] June 2024 and signed on its behalf by:
......................................... ………………………………….. Dr Jonny Coppel Dr Jess Kearney Trustee Trustee
The notes attached on pages 11 to 16 form an integral part of these accounts.
11
Asthma Innovation Research
(Registration number 1168495)
Notes forming part of the Financial Statements for the year ended 1 January 2024
1 Accounting policies
The principal accounting policies are summarised below. The accounting policies have been applied consistently throughout the year and in the preceding year.
Statement of compliance
The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.
Basis of preparation
Asthma Innovation Research meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.
Exemption from preparing a cash flow statement
The charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.
Going concern
The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.
Income and endowments
Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.
Donations and legacies
Donations and legacies are recognised on a receivable basis when receipt is probable, and the amount can be reliably measured.
Expenditure
All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a
12
Asthma Innovation Research
(Registration number 1168495)
basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use. Other support costs are allocated based on the spread of staff costs.
Raising funds
These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.
Charitable activities
Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.
Grant provisions
Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty about either the timing of the grant or the amount of grant payable.
Governance costs
These include the costs attributable to the charity’s compliance with constitutional and statutory requirements, including audit, strategic management and trustees’ meetings and reimbursed expenses.
Taxation
The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.
Research and development
Research and development expenditure is written off as incurred.
Trade debtors
are amounts due from customers for merchandise sold or services performed in the ordinary course of business are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of is established when there is objective evidence that they will not be able to collect all amounts due according to the original terms of the receivables.
13
Asthma Innovation Research
(Registration number 1168495)
Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.
Fund structure
Unrestricted income funds are general funds that are available for use at the trustees’ discretion in furtherance of the objectives of the charity. Designated funds are unrestricted funds earmarked by the trustees for particular purposes.
Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal.
Financial instruments
Classification
Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.
Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.
Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.
14
Asthma Innovation Research
(Registration number 1168495)
Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled, or expires.
Fair value measurement
The best evidence of fair value is a quoted price for an identical asset in an active market. When quoted prices are unavailable, the price of a recent transaction for an identical asset provides evidence of fair value as long as there has not been a significant change in economic circumstances or a significant lapse of time since the transaction took place. If the market is not active and recent transactions of an identical asset on their own are not a good estimate of fair value, the fair value is estimated by using a valuation technique.
2 Income from donations and legacies
| Donations and legacies: Donations from individuals Other donations Regular giving and capital donations |
Unrestricted Restricted Total Total 2024 2023 £ £ £ £ 13 - 13 - - - - - |
|---|---|
| 13 - 13 - |
3 Expenditure on raising funds
There were no costs incurred in generating the donations and voluntary income.
4 Expenditure on charitable activities
| Governance costs Costs of charitable activities |
Unrestricted Restricted Total Total 2024 2023 £ £ £ £ - - - - 52 - 52 388 |
|---|---|
| 52 - 52 388 |
15
Asthma Innovation Research
(Registration number 1168495)
5 Trustees remuneration and expenses
No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.
6 Taxation
The charity is a registered charity and is therefore exempt from taxation.
7 Debtors
No debtors were outstanding at the end of the financial year.
8 Creditors: amounts falling due within one year
No creditors were outstanding at the end of the financial year.
9 Funds
| Unrestricted funds General Restricted funds General |
Balance at Incoming Resources Balance at 2 January 2023 resources expended 1 January 2024 2,232 13 (52) 2193 |
|---|---|
| Balance at Incoming Resources Balance at 2 January 2023 resources expended 1 January 2024 - - - - |
16
Asthma Innovation Research
(Registration number 1168495)
10 Analysis of net assets between funds
| Current assets Net assets at 1 January 2024 |
General Designated Restricted Total Funds Funds Funds Funds 2,193 - - 2,193 |
|---|---|
| 2,193 - - 2,193 |
11 Analysis of net funds
| Cash at bank and in hand Net funds |
At 2 January 2023 £ 2,232 2,232 |
Cash flow £ At 1 January 2024 £ (39) 2,193 |
|---|---|---|
| (39) 2,193 |
17